← Leaderboards
Rathin C Das
Synergys Biotherapeutics, Inc.
$650,000
Attributed
$1,000,000
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $400K · FY2017–22$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,000,000 · 3
By mechanism
R43$600,000 · 2
R44$400,000 · 1
Top collaborators
- Joseph D. Rosenblatt2 shared
Others in their field
Other Emerging Leaders on “Serum”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Maria C Carrillo · Indiana University Indianapolis$19,445,642
- Amit Singal · Ut Southwestern Medical Center$13,798,031
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,916,531
- Quy Phung · Leidos Biomedical Research, Inc.$12,889,396
- Xinhua Li · Nano Terra, Inc.$11,941,250
Research focus
SerumBlood VesselsMda Mb 231Neoplasm MetastasisTherapeutic TargetTumor GrowthIgg1Malignant Breast NeoplasmMimicryChemotherapyDimerEpidermal Growth Factor ReceptorTriple-Negative Invasive Breast CarcinomaEndostatinsChinese Hamster Ovary CellGrowthCell MotilityIn VivoAngiogenesisChimeric ProteinsAntibodiesChemotherapeutic AgentAngiogenesis InhibitorsEndothelial Cells
Grant awards (3)
Development of Anti-EGFR-huEndo-P125A: A combined Vasculogenic Mimicry-Angiogenesis inhibitory therapeutic for Triple Negative Breast Cancer$400,000
R44 · FY2022 · CA · contact PI
Combined Inhibition of Vasculogenic Mimicry and Angiogenesis in Ovarian Cancer using Antibody Fusion Protein$300,000
R43 · FY2019 · CA · contact PI
Targeting angiogenesis and vasculogenic mimicry in Triple Negative Breast Cancer$300,000
R43 · FY2017 · CA · contact PI